Dawn Rubel, President R&D at NexEos Bio - Eosinophilic Esophagitis, Purposeful Leadership and more episode artwork

EPISODE · Feb 10, 2025 · 34 MIN

Dawn Rubel, President R&D at NexEos Bio - Eosinophilic Esophagitis, Purposeful Leadership and more

from A Dose of Reality with Charles Spence

In this episode, I talked with Dawn Rubel, President of R&D at NexEos Bio, where she shares her career journey from a scientific technical writer to a leadership role in biotech. She discusses her experiences at Immunomedics, the development of Trodelvy, and her transition to NexEos Bio, where she focuses on eosinophilic inflammation. Dawn emphasizes the importance of teamwork, hiring the right people, and learning from failures in clinical trials. She also provides valuable advice for aspiring leaders and highlights the significance of passion in one's work.Here's what you're in:Why did Dawn move into quality, regulatory, and leadership instead of staying in technical writing?What is the biggest lesson she learned from her career journey?Who does Nexeos Bio aim to help, and what is the company’s approach?Timestamps01:52 Dawn's Career Journey05:20 Immunomedics and Troldevy08:05 Joining Nexeos Bio 11:47 Challenges and Opportunities at NexEos Bio15:09 Failures and Lessons in Clinical Trials22:10 Insights About Hiring and Leadership 31:25 Advice for Aspiring LeadersAbout DawnDawn Rubel is the President of Research and Development at NexEos Bio, a privately held medical diagnostics and therapeutics company focused on developing innovative technologies for eosinophil-mediated diseases. Dawn has successful leadership experience in Biotech, Pharma, Medical Device from global multibillion-dollar corporations (Pfizer, Arthrex) to small biotechs (Immunomedics, NexEos Bio). She held leadership roles in safety, quality, & regulatory in her previous companies. She earned an MBA in Fairleigh Dickinson University and she did her Graduate Studies in Industrial Pharmacy, Pharmaceutics and Drug Design in Long Island University.Connect with DawnLinkedIn: https://www.linkedin.com/in/dawn-rubel/ Company Website: https://www.nexeosbio.com/ About MeMy name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.Connect with me:LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/Website: https://www.discera-search.com/Opinions and comments expressed by the guest do not represent the company and are fully their own.

Episode metadata supplied by the publisher feed · Published Feb 10, 2025

Embed this episode

NOW PLAYING

Dawn Rubel, President R&D at NexEos Bio - Eosinophilic Esophagitis, Purposeful Leadership and more

0:00 34:39

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of A Dose of Reality with Charles Spence?

This episode is 34 minutes long.

When was this A Dose of Reality with Charles Spence episode published?

This episode was published on February 10, 2025.

Can I download this A Dose of Reality with Charles Spence episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!